[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624490":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":73,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group: Anakinra during EVLP","EXPERIMENTAL","One dose (100mg) Anakinra will be injected into the perfusion solution during ex vivo lung perfusion (EVLP) prior to lung transplant.",[13],"Drug: Anakinra",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Control group will not receive Anakinra during EVLP.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Anakinra","100 mg injection",[9],[26],{"name":27,"affiliation":5,"role":28},"Chitaru Kurihara, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Mary Carns, MS","CONTACT","312-503-1137","m-carns@northwestern.edu",[36],{"facility":5,"status":18,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Chicago","Illinois","60611","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-87.65005,41.85003,{"lat":46,"lon":45},[49,50],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},{"name":27,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":28,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Chitaru Kurihara","Assistant Professor of Surgery","100624490","early-phase-1-bridge---blocking-receptor-of-il-1-for-donor-graft-edema-reduction-100624490",false,"NCT07410312","BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction","Inclusion Criteria:\n\n* Age 18 years or older.\n* Planning to undergo transplantation of the lung.\n* Willing and able to read, understand, and be capable of giving informed consent.\n* Use of ex vivo lung perfusion (EVLP) prior to lung transplant.\n\nExclusion Criteria:\n\n* Previous or current use of IL-1R antagonist drug.\n* Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.","ALL","18 Years",{"count":63,"type":64},20,"ESTIMATED","INTERVENTIONAL",[67],"EARLY_PHASE1","This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.",[70],"Lung Transplant Recipient",[72],"lung transplant","NOT_YET_RECRUITING","2026-06-24",{"date":76,"type":77},"2026-06-25","ACTUAL",{"date":79,"type":64},"2026-07-01",{"date":81,"type":64},"2027-12",{"name":5,"class":6},1]